Study of the role of local treatments on the modulation of the microbiome in psoriatic skin - Microbiome & Psoriasis Study

CHU de Nice0 sites30 target enrollmentApril 11, 2018

Overview

No summary available.

Registry

who.int

Start Date

April 11, 2018

End Date

TBD

Last Updated

7 years ago

Study Type

Interventional clinical trial of medicinal product

Sponsor

•1\. Patients of both more than 18\-year\-old sexes having signed and dated a form of information and informed consent.
•2\. Subject presenting a psoriasis vulgaris with symmetric hurts in size and in severity, located on elbows and\\or knees and having a score of severity (PASI)\< 10\. The hurts will have to have a surface of at least 4 cms ².
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1\.2 Adults (18\-64 years) yes
•F.1\.2\.1 Number of subjects for this age range 28
•F.1\.3 Elderly (\>\=65 years) yes
•F.1\.3\.1 Number of subjects for this age range 2

•1\. Subject presenting a psoriasis in drop(gout), érythrodermique, exfoliatif or pustuleux.
•2\. Feminine Subject pregnant or breast\-feeding.
•3\. Subject having received a systematic treatment(processing) and having a potential action(share) on the psoriasis vulgaris (ex: phototherapy, cyclosporine, méthotrexate, biotherapics, steroids, or other immunosuppresseurs treatments(processings)) in 2 months preceding the randomization and during all the duration the study.
•4\. Subject having received a treatment(processing) antibiotic in the previous three months the visit of inclusion
•5\. Subject having received the topical treatments(processings) (example: corticostéroïdes, tazarotène, analogues of the vitamin D) or neutral emollients in 4 weeks preceding the randomization